CN114539383A - 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构的制备方法和应用 - Google Patents
一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构的制备方法和应用 Download PDFInfo
- Publication number
- CN114539383A CN114539383A CN202210176728.4A CN202210176728A CN114539383A CN 114539383 A CN114539383 A CN 114539383A CN 202210176728 A CN202210176728 A CN 202210176728A CN 114539383 A CN114539383 A CN 114539383A
- Authority
- CN
- China
- Prior art keywords
- protein
- human annexin
- crystal structure
- mutant
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 82
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 title claims abstract description 63
- 102000054215 human ANXA5 Human genes 0.000 title claims abstract description 48
- 239000000539 dimer Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 60
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000002425 crystallisation Methods 0.000 claims abstract description 12
- 230000008025 crystallization Effects 0.000 claims abstract description 12
- 238000005457 optimization Methods 0.000 claims abstract description 10
- 239000012460 protein solution Substances 0.000 claims abstract description 10
- 238000013537 high throughput screening Methods 0.000 claims abstract description 9
- 239000013612 plasmid Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 7
- 239000013604 expression vector Substances 0.000 claims abstract description 7
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 4
- 238000005520 cutting process Methods 0.000 claims abstract description 4
- 238000001514 detection method Methods 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 239000002808 molecular sieve Substances 0.000 claims description 16
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 102000000412 Annexin Human genes 0.000 claims description 13
- 108050008874 Annexin Proteins 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000012505 Superdex™ Substances 0.000 claims description 4
- 241001052560 Thallis Species 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 235000019750 Crude protein Nutrition 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 3
- 102000008300 Mutant Proteins Human genes 0.000 abstract description 2
- 108010021466 Mutant Proteins Proteins 0.000 abstract description 2
- 239000003596 drug target Substances 0.000 abstract 1
- 238000012827 research and development Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 40
- 102100034283 Annexin A5 Human genes 0.000 description 15
- 238000011160 research Methods 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 229950006137 dexfosfoserine Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 108010038633 aspartylglutamate Proteins 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- AXHNAGAYRGCDLG-UWVGGRQHSA-N Met-Lys-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AXHNAGAYRGCDLG-UWVGGRQHSA-N 0.000 description 2
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108010000998 wheylin-2 peptide Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 1
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 1
- CXQODNIBUNQWAS-CIUDSAMLSA-N Ala-Gln-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CXQODNIBUNQWAS-CIUDSAMLSA-N 0.000 description 1
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 1
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 1
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
- BGGAIXWIZCIFSG-XDTLVQLUSA-N Ala-Tyr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O BGGAIXWIZCIFSG-XDTLVQLUSA-N 0.000 description 1
- ZJLORAAXDAJLDC-CQDKDKBSSA-N Ala-Tyr-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ZJLORAAXDAJLDC-CQDKDKBSSA-N 0.000 description 1
- NXDXECQFKHXHAM-HJGDQZAQSA-N Arg-Glu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NXDXECQFKHXHAM-HJGDQZAQSA-N 0.000 description 1
- KRQSPVKUISQQFS-FJXKBIBVSA-N Arg-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N KRQSPVKUISQQFS-FJXKBIBVSA-N 0.000 description 1
- YVTHEZNOKSAWRW-DCAQKATOSA-N Arg-Lys-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O YVTHEZNOKSAWRW-DCAQKATOSA-N 0.000 description 1
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 1
- HOIFSHOLNKQCSA-FXQIFTODSA-N Asn-Arg-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O HOIFSHOLNKQCSA-FXQIFTODSA-N 0.000 description 1
- CDGHMJJJHYKMPA-DLOVCJGASA-N Asn-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)N)N CDGHMJJJHYKMPA-DLOVCJGASA-N 0.000 description 1
- ZCKYZTGLXIEOKS-CIUDSAMLSA-N Asp-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N ZCKYZTGLXIEOKS-CIUDSAMLSA-N 0.000 description 1
- FKBFDTRILNZGAI-IMJSIDKUSA-N Asp-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O FKBFDTRILNZGAI-IMJSIDKUSA-N 0.000 description 1
- IJHUZMGJRGNXIW-CIUDSAMLSA-N Asp-Glu-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IJHUZMGJRGNXIW-CIUDSAMLSA-N 0.000 description 1
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 1
- RXBGWGRSWXOBGK-KKUMJFAQSA-N Asp-Lys-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RXBGWGRSWXOBGK-KKUMJFAQSA-N 0.000 description 1
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 1
- BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 1
- ZUNMTUPRQMWMHX-LSJOCFKGSA-N Asp-Val-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O ZUNMTUPRQMWMHX-LSJOCFKGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- DWGWCWDDNTVOGF-UHFFFAOYSA-N Cl.Cl.Cl.Cl.Cl.Cl Chemical compound Cl.Cl.Cl.Cl.Cl.Cl DWGWCWDDNTVOGF-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- KJRXLVZYJJLUCV-DCAQKATOSA-N Gln-Arg-Met Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O KJRXLVZYJJLUCV-DCAQKATOSA-N 0.000 description 1
- KDXKFBSNIJYNNR-YVNDNENWSA-N Gln-Glu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KDXKFBSNIJYNNR-YVNDNENWSA-N 0.000 description 1
- HXOLDXKNWKLDMM-YVNDNENWSA-N Gln-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HXOLDXKNWKLDMM-YVNDNENWSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- BUAKRRKDHSSIKK-IHRRRGAJSA-N Glu-Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BUAKRRKDHSSIKK-IHRRRGAJSA-N 0.000 description 1
- LGYCLOCORAEQSZ-PEFMBERDSA-N Glu-Ile-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O LGYCLOCORAEQSZ-PEFMBERDSA-N 0.000 description 1
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 1
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 1
- MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 description 1
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- FIQQRCFQXGLOSZ-WDSKDSINSA-N Gly-Glu-Asp Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FIQQRCFQXGLOSZ-WDSKDSINSA-N 0.000 description 1
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 1
- YOTNPRLPIPHQSB-XUXIUFHCSA-N Ile-Arg-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOTNPRLPIPHQSB-XUXIUFHCSA-N 0.000 description 1
- PHRWFSFCNJPWRO-PPCPHDFISA-N Ile-Leu-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N PHRWFSFCNJPWRO-PPCPHDFISA-N 0.000 description 1
- PARSHQDZROHERM-NHCYSSNCSA-N Ile-Lys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)N PARSHQDZROHERM-NHCYSSNCSA-N 0.000 description 1
- HJDZMPFEXINXLO-QPHKQPEJSA-N Ile-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N HJDZMPFEXINXLO-QPHKQPEJSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 1
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
- JKSIBWITFMQTOA-XUXIUFHCSA-N Leu-Ile-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O JKSIBWITFMQTOA-XUXIUFHCSA-N 0.000 description 1
- PDQDCFBVYXEFSD-SRVKXCTJSA-N Leu-Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PDQDCFBVYXEFSD-SRVKXCTJSA-N 0.000 description 1
- IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 description 1
- FIICHHJDINDXKG-IHPCNDPISA-N Leu-Lys-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O FIICHHJDINDXKG-IHPCNDPISA-N 0.000 description 1
- IBSGMIPRBMPMHE-IHRRRGAJSA-N Leu-Met-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O IBSGMIPRBMPMHE-IHRRRGAJSA-N 0.000 description 1
- BIZNDKMFQHDOIE-KKUMJFAQSA-N Leu-Phe-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 BIZNDKMFQHDOIE-KKUMJFAQSA-N 0.000 description 1
- KQFZKDITNUEVFJ-JYJNAYRXSA-N Leu-Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=CC=C1 KQFZKDITNUEVFJ-JYJNAYRXSA-N 0.000 description 1
- INCJJHQRZGQLFC-KBPBESRZSA-N Leu-Phe-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O INCJJHQRZGQLFC-KBPBESRZSA-N 0.000 description 1
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- TXTZMVNJIRZABH-ULQDDVLXSA-N Lys-Val-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TXTZMVNJIRZABH-ULQDDVLXSA-N 0.000 description 1
- IUYCGMNKIZDRQI-BQBZGAKWSA-N Met-Gly-Ala Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O IUYCGMNKIZDRQI-BQBZGAKWSA-N 0.000 description 1
- WXJLBSXNUHIGSS-OSUNSFLBSA-N Met-Thr-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WXJLBSXNUHIGSS-OSUNSFLBSA-N 0.000 description 1
- 101001033003 Mus musculus Granzyme F Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- YYRCPTVAPLQRNC-ULQDDVLXSA-N Phe-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC1=CC=CC=C1 YYRCPTVAPLQRNC-ULQDDVLXSA-N 0.000 description 1
- PSKRILMFHNIUAO-JYJNAYRXSA-N Phe-Glu-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N PSKRILMFHNIUAO-JYJNAYRXSA-N 0.000 description 1
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 1
- XZQYIJALMGEUJD-OEAJRASXSA-N Phe-Lys-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZQYIJALMGEUJD-OEAJRASXSA-N 0.000 description 1
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 1
- UTAUEDINXUMHLG-FXQIFTODSA-N Pro-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 UTAUEDINXUMHLG-FXQIFTODSA-N 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 1
- JFWDJFULOLKQFY-QWRGUYRKSA-N Ser-Gly-Phe Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JFWDJFULOLKQFY-QWRGUYRKSA-N 0.000 description 1
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 description 1
- YIUWWXVTYLANCJ-NAKRPEOUSA-N Ser-Ile-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O YIUWWXVTYLANCJ-NAKRPEOUSA-N 0.000 description 1
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 1
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 1
- CRZNCABIJLRFKZ-IUKAMOBKSA-N Thr-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N CRZNCABIJLRFKZ-IUKAMOBKSA-N 0.000 description 1
- FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- XYBNMHRFAUKPAW-IHRRRGAJSA-N Tyr-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N XYBNMHRFAUKPAW-IHRRRGAJSA-N 0.000 description 1
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 1
- VLDMQVZZWDOKQF-AUTRQRHGSA-N Val-Glu-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VLDMQVZZWDOKQF-AUTRQRHGSA-N 0.000 description 1
- MJFSRZZJQWZHFQ-SRVKXCTJSA-N Val-Met-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)O)N MJFSRZZJQWZHFQ-SRVKXCTJSA-N 0.000 description 1
- DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 1
- PFMSJVIPEZMKSC-DZKIICNBSA-N Val-Tyr-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N PFMSJVIPEZMKSC-DZKIICNBSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102000014823 calbindin Human genes 0.000 description 1
- 108060001061 calbindin Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- RDYMFSUJUZBWLH-UHFFFAOYSA-N endosulfan Chemical compound C12COS(=O)OCC2C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl RDYMFSUJUZBWLH-UHFFFAOYSA-N 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- -1 isopropyl- Chemical group 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108010022588 methionyl-lysyl-proline Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001010 protein structure resolution Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 108010005652 splenotritin Proteins 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种人源膜联蛋白A5突变体二聚体的晶体结构的制备方法，包括如下步骤：（1）将人源膜联蛋白A5的基因序列通过EcoRⅠ和XholⅠ酶切位点连接至pET‑28a(+)质粒上，将表达载体转入宿主大肠杆菌BL21(DE3)中表达，通过亲和层析纯化，获得高纯度蛋白；（2）将蛋白浓缩为10 mg/mL的蛋白水溶液，将蛋白溶液与池液混合，采取坐滴法对结晶条件进行高通量筛选；对结晶条件进行正交优化，制得人源膜联蛋白A5突变体二聚体的晶体结构。本发明所提供的突变体蛋白的结构信息可以用于更高效地开展制备检测试剂、诊断试剂盒制备、药物靶点筛选和治疗效果更好的变体蛋白研发，满足生物制药应用的要求。
Description
技术领域
本发明涉及医药工程技术领域，具体涉及一种人源膜联蛋白A5突变体二聚体的晶体结构的制备方法和应用。
背景技术
研究表明，膜联蛋白A5（Annexin A5）简称ANXA5，是一种320个氨基酸组成的单链蛋白，研究早期其又被称为胎盘抗凝蛋白 I、凝血酶抑制剂 V、内皮素 II、钙结合蛋白 I和脂皮质素 V。早在 1985 年，研究报道将其描述为血管抗凝剂，之后它又成为第一个被表征三维结构的膜联蛋白，表明对其的结构解析具有十分重要的研究价值。
研究表明，ANXA5蛋白结构重复序列 I 至 IV 组成，其蛋白序列 226 位上的 ASP以Ca2+和 pH 依赖的构象方式参与调控分子开关。ANXA5与 Ca2+结合时的构象，发现在ANXA5 重复序列 III 第 187 位上暴露的 Trp 与磷脂结合，此外，ANXA5 内部的域间形成了由 I/IV 和 II/III 组成的交互作用方式。其中，I和 IV 之间的相互作用是由 NH2 末端以非共价方式介导产生，而重复序列 II 和III 通过短螺旋转动方式共价连接。
研究表明， ANXA5 是一种单体结构，但与磷脂膜结合时，三个 ANXA5 单体会自发形成三聚体，而形成的三聚体可以通过三聚体-三聚体相互作用的方式在暴露有磷脂酞丝氨酸（PS）的表面组装。在涉及到抗炎、纤溶和抗血栓过程中，细胞内的 ANXA5 会在二维晶格中自组装，进而改变细胞膜的曲率以及细胞形状，最终促进细胞膜的修复。
研究表明，细胞内的 ANXA5 在质膜上表现出钙通道活性，它能与血小板中的肌动蛋白相互作用，是凝血过程的关键调节因子。另外，在血液凝固过程中需要血小板的激活，以形成一个以PS为主的磷脂膜催化表面，使凝血因子X、凝血酶原等凝血固子活化。由于膜联蛋白具有较强的钙依赖性磷脂结合活性，因而能够竞争性抑制凝血因子和血小板膜磷脂的结合，从而抑制了凝血因子X等的活化，起到抗凝血的作用。
综上所述，Annexins是一类钙离子依懒型的磷脂结合蛋白，能够调控抗凝血、细胞凋亡、信号转导等过程，并参与多种疾病的发生发展。ANXA5是膜联蛋白家族分布最多和最广泛的成员，最早被称为抗凝蛋白，主要起抗凝血的功能，通常作为抗凝剂和抗血栓形成的药。近几年，对于寻找与PS结合能力更强、抗血栓能力更强和毒性更小的ANXA5突变体成为研究热点。本发明提供了一个构建此类突变体的新思路，即通过在ANXA5的C末端添加一个半胱氨酸，能够通过形成分子间的二硫桥的构建提高分子间的聚集作用，在竞争性抑制凝血因子和血小板膜磷脂的结合中发挥更强的作用。
目前，X-射线单晶衍射方法是通过蛋白质单晶获得其三维结构的最重要的研究方法之一。对于X-射线单晶衍射方法，蛋白质单晶必须达到足够大的尺寸和完善程度。然而，由于溶液中蛋白质分子之间的相互作用位点较少，相互作用力比较弱，蛋白质晶体中往往含有很大比重的水，因此，内部结构比较规整的蛋白质晶体仍旧很难获得。获得高质量的蛋白质晶体仍旧是蛋白质结构解析的瓶颈问题。
发明内容
本发明提供了一种人源膜联蛋白A5突变体二聚体的晶体结构的制备方法和应用。
为了解决现有技术的问题，本发明提供了如下技术方案：本发明的一种所述的人源膜联蛋白A5突变体二聚体的晶体结构的制备方法，包括如下步骤：（1）将人源膜联蛋白的基因序列通过EcoRⅠ和Xhol Ⅰ酶切位点连接至pET-28a(+)质粒上，将表达载体转入宿主大肠杆菌BL21(DE3)中表达，通过亲和层析纯化，获得高纯度蛋白；
（2）将蛋白浓缩为10 mg/mL的蛋白水溶液，将蛋白溶液与池液混合，采取坐滴法对结晶条件进行高通量筛选；对结晶条件进行正交优化，制得人源膜联蛋白A5突变体二聚体的晶体结构。
进一步地，在步骤（1）中，将人源膜联蛋白A5突变体二聚体基因序列与pET-28a(+)质粒相连接，将表达载体转入宿主菌BL 21(DE 3)中表达，可获得可溶表达产物；培养条件是：采用LB培养基培养，按照2%比例扩大培养，培养到一定时间加入IPTG诱导，诱导时间为20 h；离心收集菌体超声破碎，离心收集上清液，用亲和层析柱进行蛋白粗酶液的纯化，最后用10 KD横纵切向流超滤膜获得浓缩后的高浓度蛋白溶液；利用Hiload 16/60 Superdex200分子筛进一步纯化蛋白，实验流程为：先用1.2倍柱体积的Buffer（10 mM Tris，100 mMNaCl，pH 8.5）平衡分子筛，流速1 mL/min；将5 mL 离心后的蛋白加载到分子筛，收集洗脱的蛋白，并用SDS-PAGE鉴定。
在步骤（2）中，将分子筛纯化后的蛋白浓缩到 10 mg/mL，用坐滴法对初始结晶条件进新了高通量筛选, 共筛选出了10个结晶kit；2天后，在含有0.2 µl 蛋白和0.2 µl 池液的结晶液滴中长出了晶体；对培养条件进行优化，优化后，含有2 µl 蛋白溶液和1 µl 池液的结晶液滴中长出的晶体符合要求。
进一步地，在步骤（2）中，所述的池液含有0.2 M氯化钠，0.1 M 4-羟乙基哌嗪乙磺酸的pH为 6.5-7.5和16%-26%聚乙二醇单甲醚3000。
进一步地，在步骤（2）中，所述的池液含有0.2 M氯化钠，0.1 M 4-羟乙基哌嗪乙磺酸pH 7.2和22%聚乙二醇单甲醚3000。
本发明所述的一种所述的人源膜联蛋白A5突变体二聚体的晶体结构的制备方法所制备和解析的人源膜联蛋白A5突变体二聚体的晶体结构在制备检测试剂、诊断试剂盒以及药物中的应用。
本发明的一种人源膜联蛋白突变体二聚体的晶体结构的制备方法，所述的人源膜联蛋白A5突变体二聚体的晶体结构的氨基酸序列如SEQ ID NO.1所示。
所述的人源膜联蛋白A5突变体二聚体的晶体结构的一个晶格由4个蛋白分子组成，分别为：chain A、chain B、chain C、chain D。
有益效果：本发明可以用于设计和/或修改膜联蛋白A5以提高其抗凝血、抗炎症、识别凋亡细胞等作用，提高稳定性等方面，满足生物制药应用的要求。
与现有技术相比，本发明具有如下优点：
（1）本发明在分子水平的基础上解析了人源膜联蛋白A5突变体二聚体的晶体结构。晶体结构及其衍生出的信息适用于设计和鉴定新药物，适用于设计具有高稳定性和药效的突变体蛋白。本发明可用于诸如，改善蛋白稳定性、提高药物疗效、降低药物毒性、构建ANXA5突变体库、医药领域筛选抑制剂等方面。
（2）本发明提供了解析膜联蛋白晶体结构的方法，通过该方法成功获得人源膜联蛋白ANXA5突变体二聚体的晶体结构。本发明公布的人源膜联蛋白A5突变体二聚体晶体结构信息可用于解释基于构效关系的膜联蛋白抗凝血、抗炎症、识别凋亡细胞等活性的机制。本发明提供的ANXA5突变体结构完整，保留氨基酸信息全面，为ANXA5的研究提供了更加详细的结构信息。
附图说明
图1为本发明的人源膜联蛋白A5突变体二聚体经过分子筛进一步纯化之后的SDS-PAGE电泳结果。
图2为本发明的人源膜联蛋白A5突变体二聚体高通量筛选的片状晶体示意图。
图3为本发明的人源膜联蛋白A5突变体二聚体优化后的块状晶体示意图。
具体实施方式
下面通过实施例对本发明做进一步说明，但本发明不受实施例的限制。
实施例1
本发明的一种人源膜联蛋白A5突变体二聚体的晶体结构，采用技术方案如下：本发明的一种人源膜联蛋白A5突变体二聚体的晶体结构，所述的人源膜联蛋白A5突变体二聚体的晶体结构的氨基酸序列如SEQ ID NO.1所示。
所述的人源膜联蛋白A5突变体二聚体的晶体结构的一个晶格由4个蛋白分子组成，分别为：chain A、chain B、chain C、chain D。
本发明的一种人源膜联蛋白A5突变体二聚体的晶体结构的制备方法，包括如下步骤：（1）将人源膜联蛋白A5突变体的基因序列通过EcoRⅠ和Xhol Ⅰ酶切位点连接至pET-28a(+)质粒上，将表达载体转入宿主大肠杆菌BL21(DE3)中表达，通过亲和层析纯化，获得高纯度蛋白；
（2）将蛋白浓缩为10 mg/mL的蛋白水溶液，将蛋白溶液与池液混合，采取坐滴法对结晶条件进行高通量筛选；对结晶条件进行正交优化，制得人源膜联蛋白A5突变体二聚体的晶体结构。所述的池液含有0.2 M氯化钠，0.1 M 4-羟乙基哌嗪乙磺酸的pH为 6.5和16%聚乙二醇单甲醚3000。
本发明的一种人源膜联蛋白A5突变体二聚体的晶体结构的制备方法，包括如下步骤：在步骤（1）中，将人源膜联蛋白A5突变体基因序列与pET-28a(+)质粒相连接，将表达载体转入宿主菌BL 21(DE 3)中表达，可获得可溶表达产物；培养条件是：采用LB培养基培养，按照2%比例扩大培养，培养到一定时间加入IPTG诱导，诱导时间为20 h；离心收集菌体超声破碎，离心收集上清液，用亲和层析柱进行蛋白粗酶液的纯化，最后用10 KD横纵切向流超滤膜获得浓缩后的高浓度蛋白溶液；利用Hiload 16/60 Superdex 200分子筛进一步纯化蛋白，实验流程为：先用1.2倍柱体积的Buffer（10 mM Tris，100 mM NaCl，pH 8.5）平衡分子筛，流速1 mL/min；将5 mL 离心后的蛋白加载到分子筛，收集洗脱的蛋白，并用SDS-PAGE鉴定。
在步骤（2）中，将分子筛纯化后的蛋白浓缩到 10 mg/mL，用坐滴法对初始结晶条件进新了高通量筛选, 共筛选出了10个结晶kit；2天后，在含有0.2 µl 蛋白和0.2 µl 池液的结晶液滴中长出了晶体；对培养条件进行优化，优化后，含有2 µl 蛋白溶液和1 µl 池液的结晶液滴中长出的晶体符合要求。所述的池液含有0.2 M氯化钠，0.1 M 4-羟乙基哌嗪乙磺酸pH 7.2和22%聚乙二醇单甲醚3000。
本发明所述的人源膜联蛋白人源膜联蛋白A5突变体二聚体的晶体结构在制备检测试剂、诊断试剂盒以及药物中的应用。
实施例2
实施例2与实施例1的区别在于：
所述的池液含有0.2 M氯化钠，0.1 M 4-羟乙基哌嗪乙磺酸的pH为 7.5和26%聚乙二醇单甲醚3000。
试验例1
人源膜联蛋白A5突变体二聚体的表达与纯化
人工合成编码人源膜联蛋白A5突变体的 DNA序列。用双酶切位点（EcoRⅠ和XholⅠ）连入 pET-28 a（+）载体中。将重组质粒转化大肠杆菌 BL 21(DE3) 感受态细胞，将所得到的转化子克隆挑取转接入适量 LB 培养基（加入卡那霉素至终浓度为50 μg/mL）中，37℃培养至 600 nm 吸光度为0.8，加入诱导剂异丙基-β-D-硫代吡喃半乳糖苷（IPTG）至终浓度为 0.5 mM，20℃诱导20 h。以4200 r/min离心30 min 收取菌体后，用缓冲液：20 mM Tris-HCl（三羟甲基氨基甲烷-盐酸），pH 8.0 以菌体：缓冲液=1（g）：10（mL）比例加入缓冲液使菌体重悬。菌体重悬，高压破碎后，以12000 r/min低温离心40 min去除沉淀和其他颗粒状杂质。将离心后上清液与Ni-NTA亲和介质结合后，用含有500 mM氯化钠、100 mM磷酸盐缓冲液、20 mM咪唑的缓冲液冲洗介质，去除杂蛋白。最终用含有500 mM氯化钠、100 mM磷酸盐缓冲液、500 mM咪唑的洗脱液将目的蛋白从亲和介质上洗脱下来，收集各个不同浓度洗脱液的峰尖蛋白，利用SDS-PAGE电泳检测。以10 KD横纵切向流超滤膜将洗脱液浓缩并更换至20mM Tris-HCl，pH 8.5的缓冲液里储存，用液氮速冻后放置-80℃冰箱保存。
试验例2
人源膜联蛋白A5突变体二聚体晶体的筛选与优化
缓冲液: 10 mM Tris-HCl、100 mM NaCl pH 8.5；分子筛：Hiload 16/60Superdex 200
实验流程：先用1.2倍柱体积的缓冲液平衡分子筛，流速为1 mL/min；将5ml 离心后的蛋白加载到分子筛，收集洗脱的蛋白，并用SDS-PAGE电泳鉴定 (结果如图1所示)。
将经过分子排阻层析纯化后的蛋白浓缩到 10 mg/mL，用坐滴法对初始结晶条件进新了高通量筛选，共筛选了10个结晶kit。2天后，于16摄氏度，在含有0.2 µl 蛋白和0.2µl 池液(0.2 M 氯化钠， 0.1 M HEPES pH 6.5，26 % （w/v） Polyethylene glycolmonomethyl ether 3000) 的结晶液滴中长出了晶体。 优化后，含有2 µL蛋白和1 µl池液(0.2 M 氯化钠，0.1 M HEPES pH 7.2，26% (w/v) Polyethylene glycol monomethylether 3000)的结晶液滴中长出了形状较好的晶体 (结果如图2、图3所示)。
试验例3
人源膜联蛋白A5突变体二聚体晶体结构的解析
从母液中可以获得晶体，利用液态氮气流快速冷冻，在100 K下利用X射线源获得的晶体数据，具体过程如下：
首先使用的尼龙晶体环（如Hampton Research公司的），从晶体浸泡液中获取适宜X射线衍射的晶体，并迅速使用冷却系统（如Oxford Cryosystem公司的）产生的低温氮气流中冷冻至零下150-180℃；使X射线通过晶体，利用旋进法收集X射线衍射数据。收集到晶体的X射线衍射数据后，按照下述步骤进行相应的数据处理：首先使用HKL2000等软件对上一步骤中收集得到的衍射数据进行处理，获得完整的数据文件；其次，使用CCP4程序包中的Phaser、Molrep等软件，利用分子置换（MR，Molecular Replacement）方法，以已知的膜联蛋白的结构（1ANX）为搜索模型，得到人源膜联蛋白A5突变体二聚体的初始结构，再继续使用PHENIX软件对人源膜联蛋白A5突变体二聚体的初始结构进行结构优化。
人源膜联蛋白A5突变体二聚体晶体一个晶格含有4个蛋白分子，分别为：chain A、chain B、chain C、chain D。
试验例4
人源膜联蛋白A5突变体二聚体的晶体空间结构特征
该人源膜联蛋白A5突变体二聚体晶体每个晶格有4个蛋白分子，分别为chain A、chain B、chain C、chain D。每个单分子由322个氨基酸组成，含有4个repeat重复单元。
以上所述，对本发明通过说明及具体实施方式进行了阐述，在本发明的基础上，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。
序列表
<110> 南京大学，南京吉芮康生物科技研究院有限公司
<120> 一种人源膜联蛋白A5突变体二聚体的晶体结构的制备方法及其应用
<130> 2022
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 322
<212> PRT
<213> 人工序列(人源膜联蛋白A5突变体二聚体的晶体结构的氨基酸序列)
<400> 1
Met Gly Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe
1 5 10 15
Asp Glu Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu
20 25 30
Gly Thr Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn
35 40 45
Ala Gln Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg
50 55 60
Asp Leu Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys
65 70 75 80
Leu Ile Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu
85 90 95
Leu Lys His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr
100 105 110
Glu Ile Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln
115 120 125
Val Tyr Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly
130 135 140
Asp Thr Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala
145 150 155 160
Asn Arg Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp
165 170 175
Ala Gln Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu
180 185 190
Glu Lys Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg
195 200 205
Lys Val Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu
210 215 220
Thr Ile Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala
225 230 235 240
Val Val Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu
245 250 255
Tyr Tyr Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg
260 265 270
Val Met Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu
275 280 285
Phe Arg Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp
290 295 300
Thr Ser Gly Asp Tyr Lys Lys Ala Leu Leu Leu Leu Cys Gly Glu Asp
305 310 315 320
Asp Cys
Claims (5)
1.一种人源膜联蛋白A5突变体二聚体的晶体结构的制备方法，其特征在于包括如下步骤：（1）将人源膜联蛋白A5的基因序列通过EcoRⅠ和Xhol Ⅰ酶切位点连接至pET-28a(+)质粒上，将表达载体转入宿主大肠杆菌BL21(DE3)中表达，通过亲和层析纯化，获得高纯度蛋白；
（2）将蛋白浓缩为10 mg/mL的蛋白水溶液，将蛋白溶液与池液混合，采取坐滴法对结晶条件进行高通量筛选；对结晶条件进行正交优化，制得人源膜联蛋白A5突变体二聚体的晶体结构。
2.根据权利要求1所述的人源膜联蛋白A5突变体二聚体的晶体结构的制备方法，其特征在于：在步骤（1）中，将人源膜联蛋白A5突变体基因序列与pET-28a(+)质粒相连接，将表达载体转入宿主菌BL 21(DE 3)中表达，可获得可溶表达产物；培养条件是：采用LB培养基培养，按照2%比例扩大培养，培养到一定时间加入IPTG诱导，诱导时间为20 h；离心收集菌体超声破碎，离心收集上清液，用亲和层析柱进行蛋白粗酶液的纯化，最后用10 KD横纵切向流超滤膜获得浓缩后的高浓度蛋白溶液；利用Hiload 16/60 Superdex 200分子筛进一步纯化蛋白，实验流程为：先用1.2倍柱体积的Buffer平衡分子筛，流速1 mL/min；将5 mL离心后的蛋白加载到分子筛，收集洗脱的蛋白，并用SDS-PAGE鉴定；
在步骤（2）中，将分子筛纯化后的蛋白浓缩到 10 mg/mL，用坐滴法对初始结晶条件进新了高通量筛选, 共筛选出了10个结晶kit；2天后，在含有0.2 µl 蛋白和0.2 µl 池液的结晶液滴中长出了晶体；对培养条件进行优化，优化后，含有2 µl 蛋白溶液和1 µl 池液的结晶液滴中长出的晶体符合要求。
3.根据权利要求2所述的人源膜联蛋白人源膜联蛋白A5突变体二聚体的晶体结构的制备方法，其特征在于：在步骤（2）中，所述的池液含有0.2 M氯化钠，0.1 M 4-羟乙基哌嗪乙磺酸的pH为 6.5-7.5和16%-26%聚乙二醇单甲醚3000。
4.根据权利要求3所述的人源膜联蛋白人源膜联蛋白A5突变体二聚体的晶体结构的制备方法，其特征在于：在步骤（2）中，所述的池液含有0.2 M氯化钠，0.1 M 4-羟乙基哌嗪乙磺酸pH 7.2和22%聚乙二醇单甲醚3000。
5.权利要求1至4任一项所述的人源膜联蛋白人源膜联蛋白A5突变体二聚体的晶体结构在制备检测试剂、诊断试剂盒以及药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210176728.4A CN114539383B (zh) | 2022-02-24 | 2022-02-24 | 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构的制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210176728.4A CN114539383B (zh) | 2022-02-24 | 2022-02-24 | 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构的制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114539383A true CN114539383A (zh) | 2022-05-27 |
| CN114539383B CN114539383B (zh) | 2024-03-26 |
Family
ID=81679516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210176728.4A Active CN114539383B (zh) | 2022-02-24 | 2022-02-24 | 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构的制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114539383B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102690345A (zh) * | 2011-03-24 | 2012-09-26 | 江苏靶标生物医药研究所有限公司 | 人膜联蛋白v变体及其表达、制备和应用 |
| CN110172464A (zh) * | 2019-06-05 | 2019-08-27 | 大连博格林生物科技有限公司 | 人膜联蛋白v变体及制备方法 |
| US20210130400A1 (en) * | 2019-10-31 | 2021-05-06 | National University Corporation Hokkaido University | Nucleant enhancing nucleation of a protein crystal and protein crystallization method with the same |
| US20210347819A1 (en) * | 2015-09-17 | 2021-11-11 | Annexin Pharmaceuticals Ab | Process of manufacture of annexin v |
| CN114437197A (zh) * | 2022-02-24 | 2022-05-06 | 江苏靶标生物医药研究所有限公司 | 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构及其解析方法 |
-
2022
- 2022-02-24 CN CN202210176728.4A patent/CN114539383B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102690345A (zh) * | 2011-03-24 | 2012-09-26 | 江苏靶标生物医药研究所有限公司 | 人膜联蛋白v变体及其表达、制备和应用 |
| WO2012126157A1 (zh) * | 2011-03-24 | 2012-09-27 | 常州靶标生物医药研究所有限公司 | 膜联蛋白v变体及其表达、制备和应用 |
| US20210347819A1 (en) * | 2015-09-17 | 2021-11-11 | Annexin Pharmaceuticals Ab | Process of manufacture of annexin v |
| CN110172464A (zh) * | 2019-06-05 | 2019-08-27 | 大连博格林生物科技有限公司 | 人膜联蛋白v变体及制备方法 |
| US20210130400A1 (en) * | 2019-10-31 | 2021-05-06 | National University Corporation Hokkaido University | Nucleant enhancing nucleation of a protein crystal and protein crystallization method with the same |
| CN114437197A (zh) * | 2022-02-24 | 2022-05-06 | 江苏靶标生物医药研究所有限公司 | 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构及其解析方法 |
Non-Patent Citations (3)
| Title |
|---|
| GENPEPT: "Chain A, Annexin A5", 《GENPEPT》, vol. 1, pages 343 - 344 * |
| SEOKHO HONG: "High-resolution structures of annexin A5 in a two-dimensional array", 《JOURNAL OF STRUCTURAL BIOLOGY》, vol. 209, pages 1 - 6 * |
| 高梦月: "膜联蛋白A5 在疾病诊断与新药开发中的应用前景", 《药学进展》, vol. 43, no. 1, pages 3 - 11 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114539383B (zh) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dos Santos et al. | Renaissance of protein crystallization and precipitation in biopharmaceuticals purification | |
| Korndörfer et al. | The crystal structure of the human (S100A8/S100A9) 2 heterotetramer, calprotectin, illustrates how conformational changes of interacting α-helices can determine specific association of two EF-hand proteins | |
| Hill et al. | Crystal structure of α1: implications for protein design | |
| Clark et al. | Crystal structure of R120G disease mutant of human αB-crystallin domain dimer shows closure of a groove | |
| Mosimann et al. | X-ray crystallographic structure of recombinant eosinophil-derived neurotoxin at 1.83 Å resolution | |
| AU2004262014B2 (en) | Crystalline tumor necrosis factor receptor 2 polypeptides | |
| MXPA05001042A (es) | Un metodo para purificar preproinsulina. | |
| JP2003501035A (ja) | 安定性に関して改変されたサイトカイン | |
| Wang et al. | Structure determination of cucumber green mottle mosaic virus by X-ray fiber diffraction: Significance for the evolution of tobamoviruses | |
| CA2580881A1 (en) | Use of microproteins as tryptase inhibitors | |
| JP2013507123A (ja) | Ｃ型レクチンドメインをベースとするコンビナトリアルライブラリー | |
| JP4019432B2 (ja) | ヒトアクチビンａのリフォールディング方法 | |
| CN112941081A (zh) | 表达量高和活性强的纤连蛋白突变体的编码序列及其应用 | |
| CA3041727A1 (en) | Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling | |
| Hulgan et al. | Covalent Capture of Collagen Triple Helices Using Lysine–Aspartate and Lysine–Glutamate Pairs | |
| CN114437197A (zh) | 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构及其解析方法 | |
| CN114539383A (zh) | 一种人源膜联蛋白人源膜联蛋白a5突变体二聚体的晶体结构的制备方法和应用 | |
| Yusof et al. | Structural evidence for variable oligomerization of the N‐terminal domain of cyclase‐associated protein (CAP) | |
| Kuser et al. | The X-ray structure of a recombinant major urinary protein at 1.75 Å resolution. A comparative study of X-ray and NMR-derived structures | |
| Demircioglu et al. | Purification and structural analysis of SUN and KASH domain proteins | |
| Rossjohn et al. | Structures of thermolabile mutants of human glutathione transferase P1-1 | |
| JP2003513005A (ja) | α１β１インテグリンＩ−ドメインの結晶およびそれらの使用 | |
| CN115386009A (zh) | 一种膜联蛋白v与血管生成抑制剂融合蛋白的构建方法和应用 | |
| CN112142848A (zh) | 一种重组人胰岛素及其纯化制备方法 | |
| Bang et al. | Role of a salt bridge in the model protein crambin explored by chemical protein synthesis: X-ray structure of a unique protein analogue,[V15A] crambin-α-carboxamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |